NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq: NRXP) received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for its preservative-free ketamine Abbreviated New Drug Application. Label comments were limited to minor formatting; the company expects to submit a final label this month and anticipates a GDUFA decision in Summer 2026.
The company previously received a preliminary determination of bioequivalence. NRx says the product is U.S.-manufactured and could help augment domestic ketamine supply during current backorders; the labeling remains subject to final supervisory review.
Positive
- Preliminary FDA labeling alignment for preservative-free ketamine
- Preliminary bioequivalence determination reported
- U.S. manufacturing could augment domestic ketamine supply amid backorders
Negative
- Labeling determination remains preliminary pending final supervisory review
- Final approval still pending GDUFA decision in Summer 2026
- Regulatory timing uncertainty could delay commercial availability
News Market Reaction – NRXP
In the Apr 6 session, NRXP gained 2.27%, reflecting a moderate positive market reaction. Argus tracked a trough of -7.0% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | AI partnership | Positive | -4.6% | Announced AI-based depression monitoring partnership for psychiatry clinics. |
| Mar 24 | Full-year results | Positive | +20.3% | Reported 2025 results with cash update and favorable ketamine signals. |
| Mar 19 | Earnings date set | Neutral | -3.2% | Scheduled FY2025 earnings call and corporate update date and time. |
| Mar 17 | Bioequivalence update | Positive | -6.3% | FDA indicated no bioequivalence deficiencies for ketamine ANDA. |
| Mar 16 | NDA path clarity | Positive | +12.1% | FDA Type C minutes confirmed NDA path for NRX‑100 in depression. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive regulatory and partnership news has produced mixed reactions, with both sharp gains and selloffs, indicating inconsistent pricing of catalysts.
Over the past few weeks, NRXP has reported multiple regulatory and strategic milestones. On Mar 16, FDA Type C minutes outlined an NDA path for NRX‑100 in severe depression, followed by a positive bioequivalence communication on Mar 17 and full-year 2025 results on Mar 24. A digital psychiatry partnership was announced on Mar 30. Today’s labeling alignment letter continues the theme of stepwise de‑risking of the preservative‑free ketamine franchise.
Key Terms
generic drug user fee act regulatory
office of generic drugs regulatory
abbreviated new drug application regulatory
new drug application regulatory
fast track designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory review.
- NRx previously received a preliminary determination of bioequivalence for this product.
- The Company continues to anticipate a decision on approval under the Generic Drug User Fee Act (GDUFA) in Summer 2026.
WILMINGTON, Del., April 06, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has received a letter from the Labeling Program of the FDA Office of Generic Drugs whose only comments were limited to minor formatting changes to the proposed label for the Company's preservative-free ketamine product. The Company expects to submit the final label this month. The determination is deemed preliminary until final supervisory review of NRx’s Abbreviated New Drug Application with anticipated approval in Summer 2026.
This determination by FDA is meaningful in that NRx’s product has the potential to substantially augment the supply of US manufactured ketamine at a time when multiple suppliers of ketamine are advising the medical community that they are on backorder. NRx’s preservative free product is manufactured in the United States at a time when the FDA has deemed ketamine to be a highly strategic product and recently awarded a Commissioner’s National Priority Voucher for a new US manufacturing source of ketamine drug ingredient. A key administration focus has been the “re-shoring” of critical elements of the US drug supply.
“We deeply appreciate the FDA’s timely review of the proposed labeling for our generic drug application and look forward to an ongoing collaborative relationship,” said Dr. Jonathan C. Javitt, MD, MPH, NRx’s CEO and Chairman.”
In addition to the pending ANDA application for Preservative Free Ketamine, NRx (as announced yesterday) is preparing a New Drug Application under Fast Track Designation to expand the use of intravenous ketamine to treat patients with severe depression, who may have suicidal ideation.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
